Abstract
Most post-mortem autoradiographic studies have described striatal dopamine D2 receptor up-regulation due to chronic neuroleptic exposure. The aim of our study was to compare in-vivo striatal D2 receptor density in neuroleptic-naive and neuroleptic-free schizophrenic patients. We included 28 young (mean age: 28±8 years) acute psychotic patients meeting DSM-IV criteria for schizophrenia or schizophreniform disorder. Enrolled patients were either first-episode neuroleptic-naive (n=12) or neuroleptic-free (n=16) after a minimum washout period of 7 days. All neuroleptic-free subjects had previously received neuroleptic treatment for a median period of 3.5 years. Both groups were evaluated using standard clinical scales. In-vivo striatal D2 receptor binding was assessed by basal ganglia/frontal cortex ratios using 123I-IBZM SPECT. No statistically significant differences were found in age or clinical assessment between neuroleptic-naive and neuroleptic-free schizophrenic patients. No differences were found in the basal ganglia/frontal cortex ratios of neuroleptic-naive (1.78±0.11) and neuroleptic-free (1.81±0.15) patients. No striatal uptake laterality was observed in either group. No correlation was demonstrated between BG/FC ratios and duration of illness, period of neuroleptic exposure or time of drug washout. We conclude that our neuroleptic-naive and neuroleptic-free schizophrenic patients did not show differences in striatal D2 receptor binding, suggesting that IBZM-SPECT fails to detect D2 receptor up-regulation induced by chronic exposure to neuroleptic drugs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc’h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology 99:463–472
Bernardo M, Parellada E, Lomena F, Catafau AM, Font M, Gomez JC, Lopez-Carrero C, Gutierrez F, Pavia J, Salamero M, (2001) Double-blind olanzapine versus haloperidol D2 receptor blockade in schizophrenic patients: a baseline-endpoint 123I-IBZM SPECT study. Psychiatr Res Neuroimaging 107:87–97
Carlsson A (1988) The current status of dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179–186
Croos AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in postmortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74:122–124
Farde L, Wiesel F, Stone-Elander S, Halldin C, Nordsrom AL, Hall H, Sedvall G (1990) D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry 47:213–219
Ginovart N, Wilson AA, Richardson L, Houle S, Kapur S (2003) Antipsychotic-induced D2-receptor upregulation: differential effect of continuous versus transient D2 recepor blockade. Schizophr Res Suppl 60:241
Guy W (1976) Early Clinical Drug Evaluation Unit (ECDEU). National Institute of Mental Health, Rockville, Md., publication 76, p 338.
Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U (1994) Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51:116–123
Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Knable MB, Hyde TM, Herman MM, Carter JM, Bigelow L, Kleinman JE (1994) Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal speciments from schizophrenic patients. Biol Psychiatry 36:827–35
Kornhuber J, Schultz A, Wiltfang J, Meineke I, Gleiter CH, Zöchling R, Boissl KW, Leblhuber F, Riederer P (1999) Persistence of haloperidol in human brain tissue. Am J Psychiatry 156:885–890
Laruelle M (1998) Imaging dopamine transmission in schizophrenia—a review and meta-analysis. Q J Nucl Med 42:211–221
Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423–451
Laruelle M, D’Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB (1997) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162–174
MacKay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Synder SH (1982) Increased brain dopamine receptors in schizophrenia. Arch Gen Psychiatry 39:991–997
Ng GY, O’Dowd BF, Lee SP, Chung HT, Brann MR, Seeman P, George SR (1996) Dopamine receptor dimmers and receptor blocking peptides. Biochem Biophys Res Commun 227:200–204
Overall JE, Gorham DR (1973) The brief psychiatric rating scale. In: Lyerly SB (ed) Handbook of psychiatric rating scales, 2nd edn. National Institute of Mental Health, Clinical Research Branch, Rockville, Md., pp 23–25
Peralta V, Cuesta JM (1994) Validación de la Escala de los Síndromes Positivo y negativo (PANSS). Actas Luso Esp Neurol Psiquiatr Cienc Afines 22:171–177
Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW (1994) D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 164:16–26
Seeman P, Guan HC, Van Tol HHM (1993) Dopamine D4 receptors elevated in schizophrenia. Nature 365:411–445
Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO, Heniger GR, Charney DS, Kung HF, Alavi A, Hoffer PB, Innis RB (1992) Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine 123-IBZM. J Nucl Med 33:1964–1971
Soares JC, Innis RB (1999) Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 46:600–615
Toru M, Watanabe S, Shibuya H, Nishikawa T, Noda K, Mitsushio H, Ichikawa H, Kurumaji A, Takashima M, Mataga N (1988) Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78:121–137
Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylsiperone. Psychiatry Res 49:219–237
Verhoeff NPLG (1993) Imaging neurotransmission and neuroreceptors: physiological and pharmacological basis. In: Costa DC, Morgan GF, Lassen NA (eds) New trends in nuclear neurology and psychiatry. Libbey, London, pp 36–95
Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558–1563
Acknowledgement
This study was supported by a grant from Lilly S.A. (Protocol F-1D-SP-HGDD) to the Nuclear Psychiatric Group of IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lomeña, F., Catafau, A.M., Parellada, E. et al. Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. Psychopharmacology 172, 165–169 (2004). https://doi.org/10.1007/s00213-003-1644-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1644-2